17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
09:23 - 
Aktier/åbning: Nets dratter til bunds i grønt C20 Cap
08:28 - 
Aktier/tendens: Nets kan tage fokus i let positivt mark..
07:23 - 
Novo søger om markedsføringstilladelse til Victozas arv..
Relateret debat
10:46 - 
MACE, CV - ingen mereffekt? 26 % på ugentlig semaglutid..
10:38 - 
Novo har ingen rimelig "mer-effekt" i forhold til sin "..
10:37 - 
JA, rigtig flot Novo-mer-effekt fra kurs 400 til nu kur..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 feb
NOVO-B
Det er rygtes til USA, at Invertor1 er blevet fyret, og at der nu kun ansættes forstandige folk igen..
14
23 feb
NOVO-B
Investor1, If you dont have anything nice to say, dont say anything at all. I dont know where that c..
10
22 feb
NOVO-B
Genial konklusion, særligt efter dine egne køb, sku være gået til Louis Nielsen   
9
22 feb
NOVO-B
Bliver der flere fede mennesker i verden?  Ja   Har Novo de bedste diabetes produkter på markedet? J..
4
22 feb
NOVO-B
Om 20 år er jeg 90
4
27 feb
NOVO-B
Økonomisk Ugebrev undres som mange andre over Fruergaards fortsatte tavshed. Ganske atypisk for en n..
3
22 feb
NOVO-B
Du vrøvler...kan fortsat ikke tage dig seriøst. Så vidt jeg husker at du talt Novo aktien ned alt de..
3
22 feb
NOVO-B
Investor1: "Du er og blir en stor pauseklovn .. ville dog bare ønske.. at du fandt et andet stedet o..
3
22 feb
NOVO-B
Hold du dem i 20 år - så skal du nok være en glad mand :). Det er nu engang sådan, man tjener penge...
3
27 feb
NOVO-B
I glemte bare at tjene kassen på det... Eller ihvertfald fætter Investor 1😳
2

Aktier/tendens: Nets kan tage fokus i let positivt marked

28-02-2017 08:28:00
Tirsdag morgen kan investorernes opmærksomhed samle sig om Nets, der er kommet med regnskab for fjerde kvartal 2016.Her var toplinjen lidt bedre end ventet, men..

TDC: Norske myndigheder stiller sig i vejen for rivals opkøb

27-02-2017 15:01:50
De norske konkurrencemyndigheder overvejer at afvise en godkendelse af svenske Telias køb af det norske teleselskab Phonero, der tilbyder teleløsninger til erhv..

OPTAKT Nets Q4 28/2: Investorerne spejder efter fremtidsudsigterne

27-02-2017 13:45:34
Betalingsservicekoncernen Nets er lige nu en rimelig velkørende betalingsmaskine, og der ventes ikke de store overraskelser i tallene for fjerde kvartal, som of..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vindmølleproducent mister en tredjedel af sin værdi på tre dage
2
Aktier/middag: Genmab og Pandora taber luft før Trump-tale
3
Vestas vinder stor amerikansk mølleordre - NY
4
USA/finanshuse: Bekymring om klarhed i Trumps tale i Kongressen
5
Novo søger om markedsføringstilladelse til Victozas arvtager i Japan

Relaterede aktiekurser

Novo Nordisk B A/S 249,50 0,0% Aktiekurs uændret
Novo Nordisk A/S 35,74 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. februar 2017 10:55:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170227.1 - EUROWEB1 - 2017-02-28 10:55:44 - 2017-02-28 10:55:44 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x